2CJP, also known as 4-(4-bromo-2,5-dimethoxyphenyl)-2,3,4,5-tetrahydro-1H-2-benzazepine, is a serotonin receptor modulator of the phenethylamine, 2C, and N-benzylphenethylamine families. It is a cyclized phenethylamine analogue of 25B-NBOMe in which the N-benzylethylamine side chain has been cyclized to form a tetrahydrobenzazepine ring. The drug shows affinity for the serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors (K<sub>i</sub> = 19âÂÂ457nM and 227âÂÂ3,240nM, respectively). 2CJP was first described in the scientific literature by Michael Robert Braden of the lab of David E. Nichols at Purdue University in 2007.